| Title: |
The Lancet Commission on prostate cancer: planning for the surge in cases. |
| Authors: |
James, ND; Tannock, I; N'Dow, J; Feng, F; Gillessen, S; Ali, SA; Trujillo, B; Al-Lazikani, B; Attard, G; Bray, F; Compérat, E; Eeles, R; Fatiregun, O; Grist, E; Halabi, S; Haran, Á; Herchenhorn, D; Hofman, MS; Jalloh, M; Loeb, S; MacNair, A; Mahal, B; Mendes, L; Moghul, M; Moore, C; Morgans, A; Morris, M; Murphy, D; Murthy, V; Nguyen, PL; Padhani, A; Parker, C; Rush, H; Sculpher, M; Soule, H; Sydes, MR; Tilki, D; Tunariu, N; Villanti, P; Xie, L-P |
| Contributors: |
James, Nicholas; Al-Lazikani, Bissan; Eeles, Rosalind; Moghul, Masood; Tunariu, Nina |
| Publisher Information: |
ELSEVIER SCIENCE INC |
| Publication Year: |
2024 |
| Collection: |
The Institute of Cancer Research (ICR): Publications Repository |
| Subject Terms: |
Humans; Prostatic Neoplasms; Male |
| Subject Geographic: |
England |
| Description: |
Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040. This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it. We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10–15 years, and make recommendations on how to deal with these issues. For the Commission, we established four working groups, each of which examined a different aspect of prostate cancer: epidemiology and future projected trends in cases, the diagnostic pathway, treatment, and management of advanced disease, the main problem for most men diagnosed with prostate cancer worldwide. Throughout we have separated problems in high-income countries (HICs) from those in low-income and middle-income countries (LMICs), although we acknowledge that this distinction can be an oversimplification (some rich patients in LMICs can access high-quality care, whereas many patients in HICs, especially the USA, cannot because of inadequate insurance coverage). The burden of disease globally is already substantial, but options to improve care are already available at moderate cost. We found that late diagnosis is widespread worldwide, but especially in LMICs, where it is the norm. Early diagnosis improves prognosis and outcomes, and reduces societal and individual costs, and we recommend changes to the diagnostic pathway that can be immediately implemented. For men diagnosed with advanced disease, optimal use of available technologies, adjusted to the resource levels available, could produce improved outcomes. We also found that demographic changes (ie, changing age structures and ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
Print-Electronic; 1722; application/pdf |
| Language: |
English |
| ISSN: |
1474-547X; 0140-6736 |
| Relation: |
S0140-6736(24)00651-2; The Lancet, 2024, 403 (10437), pp. 1683 - 1722; https://repository.icr.ac.uk/handle/internal/6232 |
| Availability: |
https://repository.icr.ac.uk/handle/internal/6232 |
| Rights: |
http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.ABD49EDF |
| Database: |
BASE |